Anne McDonough thinks about medical writing, global clinical research and development, and trial design because… medical research matters.
Thanks, BBC, but please try harder!
I am glad that mainstream news organizations are keeping us updated about regulatory and scientific advances that might help to prevent or mitigate another such horrific Ebola outbreak, but they do need to learn the lingo. Radio 4 kept reporting on Saturday morning that the only “clinical trial” so far of the experimental Ebola drug… read more
What’s in the new EU Clinical Trial Regulation? Part 3: What does it mean for medical writers?
Posting of clinical trial summary results to the EudraCT database became mandatory on 21 Jul 2014. These posts will feed into the publicly accessible European Union Clinical Trials Register and thus will be available to the public. For any interventional trial in the EU that ended on or after this date, posting of results is required… read more
Another kind of pharmaceutical consulting?
Some insight from a weekend at the coast…
What’s in the new EU Clinical Trial Regulation? Part 2: New reporting requirements
Article 52 requires reporting of serious breaches of the regulation or of the protocol. A serious breach is defined in much the same way that it was in the UK legislation: a breach likely to affect to a significant degree the safety and rights of a subject or the reliability and robustness of the data… read more
Some Questions from Paul Krugman
Questions About Student Writing 1. How can we incentivize students to stop using “impact” as a verb? 2. How can we impact their writing in a way that stops them from using the word “incentivize”? 3. Can we make it a principal principle of writing that “principle” and “principal” mean different things, and you… read more